Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

22 June 2021: Original Paper

Shift in Living Kidney Donor Demographics Over the Past 50 Years in a German Transplant Center

Claudia Sommerer 1ACDEF* , Zoi Bougioukou 1BCDEF , Vasileios L. Georgiou 2CD , Arianeb Mehrabi 3E , Martin Zeier 1E

DOI: 10.12659/AOT.929693

Ann Transplant 2021; 26:e929693

Table 4 Renal function and outcome data of living kidney donors from 1967 to 2016.

Number of valid values (%760)All1967–2016N=7601967–1990N=511991–2000N=1032001–2010N=3422011–2016N=264p
Time after donation (months), mean (SD)606 (79.7)105.5 (76.6)379.2 (68.0)239.7 (43.9)112.1 (34.2)47.4 (20.6)
Age (years), mean (SD)604 (79.4)59.3 (11)65.3 (7.8)66.4 (9.2)59.2 (11.5)57.1 (10.2)
External follow-up, n (%)611 (80.4)214 (35)10 (66.7)47 (65.3)124 (44.3)33 (13.5)
Creatinine (mg/dL), mean (SD), time of discharge646 (85)1.20 (0.28)No valid values1.22 (0.20)1.20 (0.26)1.26 (0.30)0.833
CKDepi eGFR (mL/min/1.73m), mean (SD), time of discharge646 (85)60.5 (15.7)No valid values61.5 (16.0)61.5 (15.2)59.5 (15.6)0.313
MDRD eGFR (mL/min/1.73 m), mean (SD), time of discharge646 (85)55.2 (14.2)No valid values55.2 (13)56 (15.0)54.2 (13.5)0.482
Creatinine (mg/dL), mean (SD), year 1532 (70)1.13 (0.25)No valid values1.11 (0.21)1.13 (0.24)1.15 (0.25)0.755
CKDepi eGFR (mL/min/1.73 m), mean (SD), year 1532 (70)65.2 (14.9)No valid values68.8 (11.7)65.6 (14.2)64.3 (14.9)0.595
MDRD eGFR (mL/min/1.73 m), mean (SD), year 1532 (70)60.0 (12.3)No valid values63.2 (18.1)60.2 (12.0)59.4 (12.7)0.635
Creatinine (mg/dL), mean (SD), last visit576 (75.8)1.06 (0.24)0.94 (0.16)0.99 (0.20)1.03 (0.24)1.11 (0.24)
CKDepi eGFR (mL/min/1.73 m), mean (SD), last visit568 (74.7)68.1 (16.9)70.4 (14.2)69.9 (16.3)69.6 (17.9)65.8 (15.6)0.005
MDRD eGFR (mL/min/1.73 m), mean (SD), last visit568 (74.7)67.6 (16.3)70.5 (13.4)71.5 (16.4)69.2 (17.9)64.6 (14.0)0.061
CKD stage 3, n (%)* 568 (74.7)201 (35.4)1 (11.1)21 (35.0)87 (33.3)92 (38.7)0.271
CKD stage 4, n (%)** 568 (74.7)2.0 (0.4)0 (0)0 (0)1 (0.4)1 (0.4)
ESRD568 (74.7)00000
Hemoglobin (g/dL), mean (SD)554 (72.8)14.1 (1.2)14.2 (0.9)13.8 (1.3)14.1 (1.3)14.2 (1.2)0.469
Glucose (fasting) mg/dL, mean (SD)517 (68)96 (18)88 (9)100 (22)94 (19)97 (16)0.027
HbA1c ≥6.5%, n (%)517 (68)13 (2.5)0 (0)4 (8.2)5 (1.2)4 (2.7)0.065
HbA1c%, mean (SD)517 (68)5.59 (0.42)5.58 (0.3)5.79 (0.46)5.60 (0.4)5.53 (0.42)0.001
De novo hypertension, n (%)545 (71.7)124 (22.7)3 (60.0)26 (59.1)62 (33.0)33 (22.6)a
De novo diabetes mellitus, n (%)478 (62.8)11 (2.3)0 (0.0)3 (7.9)4 (1.9)4 (1.8)0.0932b
Cardiovascular events, n (%)523 (69)47 (9)4 (40)13 (21.7)20 (8.9)10 (4.4)0.00
Malignancy, n (%)521 (69)33 (6.3)1 (10)7 (11.9)14 (6.3)11 (4.8)0.246
Donor deaths, n (%)644 (84.7)22 (2.9)4 (7.8)6 (5.8)10 (2.9)2 (0.8)0.00
CKD – chronic kidney disease; CKDepi – Chronic Kidney Disease Epidemiology Collaboration; eGFR – estimated glomerular filtration rate; ESRD – end-stage renal disease; MDRD – Modification of Diet in Renal Disease; n – number; p – significance; SD – standard deviation.
* CKD stage 3, CKDepi eGFR=30–60 mL/min/1.73 m;
** CKD stage 4, CKDepi eGFR=15–30 mL/min/1.73 m.
a Post-hoc comparison of percentages between periods (de novo hypertension): 1991–2000 vs 2001–2010: p=0.0071; 1991–2000 vs 2011–2016: p
In the above post-hoc analysis, the Bonferroni correction was applied.
b Post-hoc analysis is not needed for de novo diabetes mellitus since p=0.0932 (>0.05) but is helpful for hypertension since p

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358